urolithiasis
UROLITHIASIS

Urolithiasis is the formation of urinary stones in the kidney, bladder and/or urethra.

The hallmark of obstruction in the ureter and renal pelvis is the sudden onset of excruciating, intermittent pain that radiates from the flank to the groin or to the genital area and inner thigh.

It is a painful urologic disorder that occurs in 12% of the global population and has a high recurrence rate among male patients.

Lower urinary tract symptoms that are associated with urolithiasis are urgency, frequency, urge incontinence and dysuria.

 

Follow Up

  • Obtain a single 24-hour urine specimen for known stone-formers w/in 5 months after the initiation of treatment
    • Assess the response to dietary &/or medical therapy
  • After the initial follow-up, a 24-hour urine specimen should be obtained annually or w/ greater frequency, depending on the stone activity
    • Assess patient’s adherence & metabolic response
  • Obtain periodic blood testing
  • Advise the patient to increase intake of fruits & vegetables
  • Assess for adverse effects in patients on pharmacological therapy
  • Repeat stone analysis, when available, especially in patients not responding to treatment
  • Monitor patients w/ struvite stones for re-infection w/ urease-producing organisms & utilize strategies to prevent such occurrences
  • Obtain follow-up imaging studies to assess stone growth or new formation based on stone activity [eg plain abdominal imaging, renal ultrasound (UTZ) or low-dose computed tomography (CT) scan]
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.